Non-Dilutive Capital Is on the Table: Grant Opportunities Sacramento Medical and Life Science Startups Should Be Working on Right Now

Written by Rich Foreman

Non-Dilutive Capital Is on the Table: Grant Opportunities Sacramento Medical and Life Science Startups Should Be Working on Right Now

Every founder in the MedStart community knows the fundraising math.

Venture investors want more proof than they used to. Angels are selective. And in medical and life sciences, the milestones investors want to see — data, prototypes, validation — cost real money to produce.

That is why grant funding deserves a place in almost every startup's capital strategy.

Grants are non-dilutive. Nobody takes equity. There is nothing to repay. And for research-driven companies, the federal SBIR and STTR programs exist for exactly the stage most of our member companies are in: too technical and too early for comfortable venture money, but far enough along to test whether an idea actually works.

This fall, the calendar is unusually full. Below are the opportunities our community should know about right now — what they fund, who can apply, and the deadlines that matter. They are grouped by when you need to move, not by agency, because in grant funding the deadline is usually the strategy.

First, an Honest Warning About Deadlines

One program closes tomorrow.

NCI's Innovative Molecular Analysis Technologies (IMAT) program — early-stage R61 awards up to $150,000 a year for up to three years, and advanced-development R33 awards up to $300,000 a year for up to three years, for technologies that characterize cancer at the molecular or cellular level or improve how biospecimens are handled — closes November 10.

If your application is not essentially finished, this one is not a realistic start today. We are naming it because companies that are ready should not miss it, and because it illustrates the central lesson of this post:

You do not start a grant application at the deadline. You start it at the previous deadline.

Almost everything below is actionable now precisely because its deadline is weeks or months away. That lead time is not a luxury. For federal programs, it is a requirement — registrations alone can take several weeks.

Act This Month: November Windows

CARB-X — Expressions of Interest Open November 10–23

CARB-X, the global accelerator backed by BARDA and other funders, opens the second intake of its 2026 funding round on November 10, with Expressions of Interest due by November 23 at 11:59 p.m. ET.

This round is narrow, and that is good news if you fit it. There are four themes only:

  • Direct-acting therapeutics against Gram-negative bacteria
  • Novel chemistry for the AMR (antimicrobial resistance) challenge
  • Non-vaccine prevention of neonatal sepsis
  • Diagnostics for neonatal sepsis

Companies and academic developers anywhere in the world can apply, provided they can show real drug-development capability. If your company works in infectious disease, antimicrobials, or neonatal diagnostics, this is one of the few global programs built specifically for you.

SenNet SenTecs — Due November 23

The NIH Common Fund's Cellular Senescence Network is funding SenTecs — new technologies to identify, characterize, and understand senescent cells in human tissue — through five-year, milestone-driven UG3/UH3 awards.

The numbers are substantial: up to nine awards, with up to $400,000 a year in direct costs during the two-year UG3 phase and $550,000 a year during the three-year UH3 phase. Universities, nonprofits, for-profit companies, and governments can all apply. Clinical trials are not allowed under this mechanism.

Applications are due November 23. That is two weeks — tight, but realistic for a platform or tools company that already has its science and its team in place.

ARPA-H SURPASS — Solution Summary Due November 30

ARPA-H's SURPASS program is building a simulation-augmented, real-time platform for adaptive clinical trials — essentially, better and faster ways to run trials, using statistics, AI, trial operations, and regulatory science.

The gate is a Solution Summary due November 30. You cannot submit a full proposal (due January 22, 2027) without clearing that first step.

If your company builds clinical-trial platforms, trial analytics, or trial operations tools, this summary is the single most important document on your November calendar.

December: Three Windows Worth Preparing Now

Accelerate California Innovation Grants — Nomination Window December 1–7

This is the most accessible money on this list, and it is California-only.

Through CalOSBA's Accelerate California program, innovation grants of $25,000 or $50,000 (Tier 1: proof of concept, early R&D, prototypes) and $75,000 or $100,000 (Tier 2: continuing R&D, minimum viable product, pre-commercialization) go to for-profit California businesses with fewer than 100 employees.

There is a catch that makes planning essential: you cannot apply directly. A company must be an existing client of one of California's 13 Accelerate California Hubs, complete that Hub's required technical assistance, and be nominated by the Hub. Nominations are accepted only from the 1st through the 7th of each month.

The November window has just closed. The December window opens December 1. If you are not already a Hub client, November is the month to change that — the relationship and the technical assistance have to come before the nomination, not after.

ARPA-H SPECTRA — Solution Summaries Due December 2

ARPA-H's SPECTRA program funds work on the trajectories of autism: one technical area for tools that characterize genetic, environmental, metabolic, and immune factors, and a second for federated, privacy-preserving AI platforms that can map those trajectories without centralizing sensitive data.

Solution summaries are due December 2 at 3:00 p.m. ET, and the submission portal opens November 18.

This is a narrow fit — autism diagnostics, omics, and federated health AI — but for a company in that space, ARPA-H's Other Transaction awards move faster and more flexibly than traditional grants.

ARPA-H TIGAR and the DOE SBIR/STTR Pitch — December 8 and December 16

Two more December dates for specific niches:

  • TIGAR (ARPA-H) funds tissue and organ preservation, regenerative medicine, and temperature-flexible biopreservation, with budgets up to $2 million over 18 months. The required first step, a Solution Summary Video, is due December 8.
  • The Department of Energy's Fall SBIR/STTR Phase I round offers up to $300,000 per project across 25 topics, with pitches due December 16. The topics lean toward energy, grid, cybersecurity, and scientific instrumentation — not core therapeutics — but instrumentation and platform companies in our community should read the topic list before dismissing it.

The Big One: NIH SBIR/STTR on January 5

If you read nothing else in this post, read this section.

The NIH Parent SBIR (PA-27-100) and Parent STTR (PA-27-102) announcements are the main investigator-initiated route into the largest non-dilutive funding pipeline in American life science. You propose your idea — a device, diagnostic, therapeutic, digital health tool, or research product — rather than answering someone else's topic.

The next receipt date is January 5, 2027, with another on April 5, 2027.

Budgets depend on the NIH institute you target, and they are larger than many founders expect. Several institutes list Phase I budgets of $400,000 to $700,000 and Phase II budgets of $2.5 million to $3 million. U.S. small businesses (generally 500 or fewer employees) are eligible. SBIR lets the company lead the work itself; STTR requires a formal partnership with a nonprofit research institution — which, in Sacramento, is one reason relationships with UC Davis and Sacramento State matter.

January 5 sounds far away. It is not, for three reasons:

  1. Registrations take weeks. Before you can submit, your company needs active registrations and accounts across several federal systems, and any of them can stall an application. Starting in December is starting late.
  2. You should talk to a program officer first. A short call with the relevant institute's SBIR program officer — before you write — can confirm your idea fits that institute's mission and save you from writing a full application to the wrong address. Program officers expect these calls. Make one in November.
  3. Good applications are team efforts. Specific aims, budgets, letters of support, and subaward paperwork from research partners all take coordination. The companies that win these awards treat January 5 as a project plan, not a due date.

One more to watch for academic founders: NIH has forecast a Small Business Transition Grant (PAR-27-039 / PAR-27-040) for early-career scientists moving into entrepreneurship, also expected around the January 5 cycle. It is a forecast only — applications are not yet being solicited — but postdocs and new faculty spinning out companies should be watching for the final announcement.

Start Now, Submit in March: NSF Project Pitches

The National Science Foundation's SBIR/STTR program works differently, and in one way more founder-friendly: before you write a full proposal, you submit a short Project Pitch. NSF staff review it and either invite a full proposal or tell you not to waste your time.

Phase I awards run up to $305,000 for 6 to 18 months of R&D, companies can receive up to $2 million total across the program, and NSF funds deep technology well beyond biomedicine — a good option for platform, instrumentation, and health-AI companies as well as classic life science.

The November 4 full-proposal deadline has just passed, but Project Pitches are accepted on a rolling basis, and the next full-proposal deadline is March 4, 2027. A pitch submitted this month is perfectly timed for that cycle.

How to Choose: A Simple Filter

Faced with a list like this, founders tend to make one of two mistakes: applying to everything, or applying to nothing. A grant application is a serious investment of founder time — often 100 hours or more. Spend it where four tests line up:

  1. Eligibility first. Entity type, company size, location, and stage gates eliminate most programs in minutes. Read those before the science.
  2. Fit with the funder's mission, not just your needs. Reviewers fund their program's priorities. If you have to bend your project out of shape to fit, it is the wrong program.
  3. A first step you can actually hit. Many of these programs are staged — a pitch, a summary, an Expression of Interest. The staged ones are gifts: a short document now decides whether the long one is worth writing.
  4. A deadline your registrations can survive. Work backward from the due date: registrations, program-officer call, aims page, budget, letters. If the math doesn't work, aim at the next cycle deliberately instead of submitting a weak application to this one.

Why This Matters for Sacramento

None of these programs are Sacramento programs. That is the point.

Our region has the research base — UC Davis, Sacramento State, Aggie Square, a growing clinical and life-science community — and a generation of founders building real companies. What has historically separated regions that win federal research funding from regions that don't is rarely the quality of the science. It is whether founders know the windows exist, start early enough, and have a community around them while they do the unglamorous work of registrations, budgets, and aims pages.

That connective work is what MedStart exists to do. We will keep tracking these opportunities — our community should expect regular updates as new windows open and deadlines approach — and if you are working on an application, bring it to a MedStart event or roundtable. The founder at the next table may have won the award you are chasing, and in this community, they will usually tell you how.

The money is on the table. The deadlines are real. Start with the smallest step that is due first — a Hub conversation, a program-officer call, a Project Pitch — and work backward from January 5.

Non-dilutive capital rewards the prepared. Let's be prepared.

Sources

Deadlines, amounts, and eligibility checked against funder pages November 6–9, 2026. Programs change — always confirm details on the official page for the program before applying. This post is for information only and is not funding, legal, or financial advice.

Rich Foreman
Next

Raising Capital for Medical Innovation: Lessons From 30 Years of Building Biotech Companies